Answers are grounded in this paper and cite their sources.
Evaluates muscle function indicators in chronic disease patients, suggesting improvements for sarcopenia screening.
Introduction Sarcopenia and frailty are increasingly common in Switzerland’s aging population, especially among people with chronic diseases. Muscle function has recently been recognized as a key factor for physical independence and healthy aging. There is a need to find an easily implementable test that quantify muscle function of the lower extremities. Methods We assessed skeletal muscle function and body composition in 88 participants, including 51 healthy adults (mean age = 60 ± 12 years), 20 cardiovascular outpatients (67 ± 8 years), and 17 inpatients (67 ± 12 years, 10 cardiovascular, 6 onco-internistic, 1 pulmonal), using a standardised measurement battery including bioimpedance analysis (BIA), hand grip strength (HGS), isometric knee extension (IKE), and countermovement jump (CMJ) power. All functional tests were performed four times, with the best attempt used for analysis. Pearson correlation coefficients between muscle parameters were calculated. Variables that best discriminated between healthy individuals and the two patient groups were identified by linear discriminant analysis (LDA). Predictors included sex, age, height, skeletal muscle mass (SMM), phase angle, HGS, IKE, and CMJ power. Separate logistic regression models adjusted for age, sex and height were fitted for HGS, IKE, and CMJ and their individual power to discriminate between healthy people and inpatients evaluated with the area under the curve (AUC). Results Pearson correlation coefficients revealed strong collinearity among muscle-related variables (Figure 1). LDA achieved 72% cross-validated accuracy, with the first discriminant function (LD1) explaining over 90% of the total discriminative variance. IKE contributed most strongly to group separation along LD1, followed by PhA and CMJ power, whereas SMM and HGS contributed negatively (Figure 2). Among logistic regressions, both IKE (AUC=0.96) and CMJ (AUC=0.93) showed the highest discriminatory power to separate healthy from inpatients, while HGS performed considerably worse (AUC=0.77). Conclusion Tests targeting lower extremity performance provided stronger discriminatory power between stationary patients and healthy individuals than HGS and SMM. While IKE showed the best group separation, it is more time consuming to perform than HGS. In contrast, CMJ is easy to perform and quick to administer and hence comparable to HGS, but offers better discriminatory power and additional insights into muscle function of the lower extremities. BIA adds complementary information when PhA is considered alongside SMM, however, SMM performs poorly to discriminate between patients and healthy persons. Our ongoing work on estimating CMJ power using wearable accelerometry sensors may enable an even simpler and more cost-effective approach to quantifying lower extremity muscle power. Based on these findings, we suggest including CMJ and PhA as additional components in sarcopenia pre-screening and screening protocols.
No takes yet. Share an insight, caveat, or question.
Herwegh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: